Abstract
Serine Incorporators (Serinc) are promising HIV therapeutic targets because of their ability to impair virus-target cell fusion. These all alpha-helical membrane proteins contain ten transmembrane segments, have limited extra-membranous domains, and are conserved in all eukaryotes. Human Serinc5 and Serinc3 inhibit HIV infectivity by impairing virus-target cell fusion through a proposed interaction with the HIV Env glycoprotein. However, Nef, an HIV auxiliary protein, counteracts Serinc's inhibition of membrane fusion by targeting it for degradation via clathrin-mediated endocytosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
